180 related articles for article (PubMed ID: 19201525)
1. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
Bellmunt J; Ribas A
Eur Urol; 2009 Jun; 55(6):1342-3. PubMed ID: 19201525
[No Abstract] [Full Text] [Related]
2. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
Clark PE
Eur Urol; 2009 Jun; 55(6):1343-4. PubMed ID: 19201523
[No Abstract] [Full Text] [Related]
3. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
4. Active and passive immunotherapy: vaccines and antibodies.
Oosterwijk E; Divgi C; Bander NH
BJU Int; 2007 May; 99(5 Pt B):1301-4. PubMed ID: 17441928
[No Abstract] [Full Text] [Related]
5. High-dose interleukin-2 in metastatic renal cell carcinoma.
Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
[No Abstract] [Full Text] [Related]
6. Immunotherapy and prognostic factors.
Fumagalli LA; Brivio F
J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
[No Abstract] [Full Text] [Related]
7. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
8. Is tumor response important for renal carcinoma?
Inman BA; George DJ
Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245
[No Abstract] [Full Text] [Related]
9. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
[TBL] [Abstract][Full Text] [Related]
10. Specific antitumour vaccine for renal cancer.
Fishman M; Antonia S
Lancet; 2004 Feb; 363(9409):583-4. PubMed ID: 14987879
[No Abstract] [Full Text] [Related]
11. Editorial comment on: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Novara G
Eur Urol; 2009 May; 55(5):1153-4. PubMed ID: 18930580
[No Abstract] [Full Text] [Related]
12. Editorial comment on: Observation should be considered as an alternative in management of renal masses in older and comorbid patients.
Volpe A
Eur Urol; 2009 Jun; 55(6):1428-9. PubMed ID: 19147272
[No Abstract] [Full Text] [Related]
13. Editorial comment on: Observation should be considered as an alternative in management of renal masses in older and comorbid patients.
Remzi M
Eur Urol; 2009 Jun; 55(6):1427-8. PubMed ID: 19147268
[No Abstract] [Full Text] [Related]
14. Editorial comment on: prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.
Ohlmann CH
Eur Urol; 2010 Feb; 57(2):325-6. PubMed ID: 19136198
[No Abstract] [Full Text] [Related]
15. HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC.
Ellerhorst JA; Hildebrand WH; Cavett JW; Fernandez-Vina MA; Hodges S; Poindexter N; Fischer H; Grimm EA
Urologe A; 2004 Sep; 43 Suppl 3():S137. PubMed ID: 15148575
[No Abstract] [Full Text] [Related]
16. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.
Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG
J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220
[TBL] [Abstract][Full Text] [Related]
17. Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
Mulders P
Eur Urol; 2009 Jul; 56(1):132-3. PubMed ID: 18550266
[No Abstract] [Full Text] [Related]
18. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.
Vaglio A; Alberici F; Maggiore U; Buti S; Potenzoni D; Passalacqua R; Buzio C
Oncology; 2009; 76(1):69-76. PubMed ID: 19047813
[TBL] [Abstract][Full Text] [Related]
19. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
20. Editorial Comment on: Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas.
Staehler M
Eur Urol; 2007 Oct; 52(4):1155. PubMed ID: 17287072
[No Abstract] [Full Text] [Related]
[Next] [New Search]
